oncology

Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
Fierce Biotech
Xilio Therapeutics
funding
immunotherapy
clinical trials
cancer
oncology
Yervoy
Flag link:
AstraZeneca drops breast, prostate cancer programs in Q4 pipeline cull
AstraZeneca drops breast, prostate cancer programs in Q4 pipeline cull
Fierce Biotech
AstraZeneca
oncology
AZD9496
breast cancer
imaradenant
prostate cancer
Flag link:
Amgen slams the brakes on a clutch of cancer drugs as reality BiTEs
Amgen slams the brakes on a clutch of cancer drugs as reality BiTEs
Fierce Biotech
Amgen
earnings
cancer
oncology
drug development
Flag link:
Why Cardiff Oncology Ran Up 1,350% in 2020
Why Cardiff Oncology Ran Up 1,350% in 2020
Motley Fool
Cardifff Oncology
oncology
cancer
KRAS mutation
Flag link:
Go or no go? Oncology decisions ahead for the FDA
Go or no go? Oncology decisions ahead for the FDA
EP Vantage
FDA
cancer
oncology
Bristol-Myers Squibb
TG Therapeutics
Mallinckrodt
Sanofi
Regeneron
Sarepta Therapeutics
GSK
Oncopeptide
Flag link:
Kura Oncology’s Small Molecules Hint at Major Therapeutic Breakthroughs
Kura Oncology’s Small Molecules Hint at Major Therapeutic Breakthroughs
BioSpace
cancer
oncology
Kura Oncology
personalized medicine
Flag link:
The Future of Cancer Treatment Lies in Vaccines, Say These Pioneers
The Future of Cancer Treatment Lies in Vaccines, Say These Pioneers
BioSpace
cancer
oncology
vaccines
cancer vaccines
Neuvogen
Lineage Therapeutics
BioNTech
Flag link:
Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies
Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies
Endpoints
Eli Lilly
oncology
Merus
drug discovery
Flag link:
Two Cancer Companies Close Series A Rounds Netting $144 Million
Two Cancer Companies Close Series A Rounds Netting $144 Million
BioSpace
cancer
oncology
funding
Delfi Diagnostics
Elucida Oncology
Flag link:
JPM: Bluebird to spin off cancer therapies into new company
JPM: Bluebird to spin off cancer therapies into new company
Fierce Biotech
Bluebird Bio
spinoffs
oncology
JPMHC 2021
Oncology Newco
Flag link:
FDA sideswipes Neoleukin with clinical hold on lead immunotherapy candidate, sends shares plummeting
FDA sideswipes Neoleukin with clinical hold on lead immunotherapy candidate, sends shares plummeting
Endpoints
Neoleukin
NL-201
FDA
natural killer cell therapy
oncology
clinical trials
Flag link:
Two Companies Ring in 2021 with Cash for Cancer and Rare Diseases
Two Companies Ring in 2021 with Cash for Cancer and Rare Diseases
BioSpace
funding
biotech
IconOVir Bio
oncolytic viruses
cancer
oncology
Aro Biotherapeutics
RNA
Flag link:
Ikena bags $120M to advance growing pipeline of cancer drugs
Ikena bags $120M to advance growing pipeline of cancer drugs
Fierce Biotech
Ikena Oncology
cancer
oncology
funding
Flag link:
Clinical developments over the holidays
Clinical developments over the holidays
EP Vantage
Aprea Therapeutics
Arcturus Therapeutics
Axsome Therapeutics
Inovio
Regeneron
clinical trials
oncology
vaccines
COVID-19
Flag link:
What if we captured the spirit and urgency of Covid-19 research to cure cancer?
What if we captured the spirit and urgency of Covid-19 research to cure cancer?
MedCity News
COVID-19
R&D
drug development
cancer
oncology
Flag link:
New antibody-drug conjugate partnership has oncology focus
New antibody-drug conjugate partnership has oncology focus
Biopharma Reporter
Sterling Pharma Solutions
CDMOs
oncology
cancer
antibody-drug conjugate
Flag link:
Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year
Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year
Endpoints
Vivace Therapeutics
oncology
hippo pathway
funding
Flag link:
Covid-19 Is derailing cancer clinical trials. Is new technology required to get them back on track?
Covid-19 Is derailing cancer clinical trials. Is new technology required to get them back on track?
MedCity News
data automation
clinical trials
COVID-19
pandemic
cancer
oncology
Flag link:
Better Together – Merck KGaA Announces Collaboration with Artios
Better Together – Merck KGaA Announces Collaboration with Artios
BioSpace
Merck KGaA
Artios Pharma
drug development
cancer
oncology
Flag link:
How Gilead finally spent its money
How Gilead finally spent its money
BioPharma Dive
Gilead Sciences
cancer
oncology
Flag link:

Pages